Genetic Basis of Sickle Cell Disease and Relevance to Pharmacoproteomics

Sickle cell disease (SCD) is a hereditary condition caused by a mutation in the β-globin gene, which replaces glutamic acid with valine in the β-chain of hemoglobin. SCD displays phenotypic heterogeneity in its clinical presentation and appears to be an illness affecting multiple organs and systems, leading to acute and chronic problems. The genetic basis of SCD is relevant to pharmacoproteomics as it helps understand how the genetic mutation influences the proteomic profile of individuals with SCD. This knowledge can provide insights into the molecular mechanisms underlying the disease and identify potential protein targets for therapeutic intervention. Proteomic methods, such as 2D gel electrophoresis and mass spectrometry, have contributed to diagnosing SCD and identifying potential protein targets for therapeutic intervention. Genetic polymorphisms can affect the response to SCD treatments, indicating potential genetic influences on the effectiveness of therapies. Proteomics, as a branch of functional genomics, is being utilized to pursue new drugs and identify protein targets for drug development. Genetic testing, hemoglobin electrophoresis, and hemoglobin solubility tests are currently used diagnostic techniques for SCD. In this book chapter, we reviewed the genetic basis of sickle cell disease and relevance to pharmacoproteomics.